Literature DB >> 6260009

Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.

E Melamed, F Hefti, R J Wurtman.   

Abstract

In intact striatum, the enzyme dopa decarboxylase is localized predominantly in dopaminergic nerve terminals. In Parkinson disease, loss of dopaminergic neurons is associated with massive depletion of striatal decarboxylase activity. Nevertheless, efficacy of exogenous L-dopa in parkinsonism is generally believed to result from its enzymatic decarboxylation to dopamine in the corpus striatum. It has previously been suggested that, after degeneration of nigrostriatal pathways, decarboxylation of administered L-dopa may occur mainly at such striatal sites as surviving dopaminergic terminals, serotonergic neurons, or capillaries; but currently available data do not favor these hypotheses. Recent experimental studies indicate that a substantial amount of decarboxylase activity is localized in striatal interneurons or efferent neurons that may not normally synthesize monoamines. We propose that after depletion of dopaminergic terminals, these nonaminergic striatal neurons may contain a large fraction of residual dopa decarboxylase activity and may represent an important locus for conversion of administered dopa to functional dopamine in the parkinsonian corpus striatum.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6260009     DOI: 10.1002/ana.410080603

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

1.  Diagnostic aspects of early Parkinson's disease.

Authors:  Thomas Müller; Gerd Fuchs; Matthias Hahne; Wolfgang Klein; Michael Schwarz
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

2.  Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.

Authors:  J P M Finberg; A Gross; O Bar-Am; R Friedman; Y Loboda; M B H Youdim
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 3.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 4.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

5.  Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.

Authors:  T Müller; J Welnic; S Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

6.  Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.

Authors:  R J Mandel; K G Rendahl; S K Spratt; R O Snyder; L K Cohen; S E Leff
Journal:  J Neurosci       Date:  1998-06-01       Impact factor: 6.167

Review 7.  The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Authors:  T N Chase
Journal:  Drugs       Date:  1998       Impact factor: 9.546

8.  Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.

Authors:  P A Kempster; W R Gibb; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

Review 9.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

10.  Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.

Authors:  P T Männistö; P Tuomainen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.